DC
TVTX icon

Deere & Company’s Travere Therapeutics TVTX Stock Holding History

Deere & Company’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-61,899
Closed -$1.39M – 702
2016
Q3 		$1.39M Buy
61,899
+34,963
+130% +$666K 0.07% 288
2016
Q2 		$480K Sell
26,936
-8,281
-24% -$134K 0.03% 621
2016
Q1 		$481K Buy
35,217
+11,888
+51% +$180K 0.03% 631
2015
Q4 		$450K Hold
23,329
– – 0.03% 602
2015
Q3 		$472K Buy
23,329
+1,502
+7% +$44.5K 0.03% 576
2015
Q2 		$724K Buy
+21,827
New +$598K 0.04% 494

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deere & Company's TVTX Position: Q4 2016 in Review

Deere & Company sold out of Travere Therapeutics (TVTX) in Q4 2016, closing a stake of 61,899 shares — an estimated $1.39M sold.

Deere & Company first reported a position in TVTX in Q2 2015 and held it in 6 quarters. The position peaked at $1.39M in Q3 2016. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

  • Deere & Company reported no remaining Travere Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Deere & Company sold 61,899 Travere Therapeutics shares in Q4 2016, an estimated $1.39M.
  • Deere & Company first reported a position in Travere Therapeutics in Q2 2015 and held it in 6 quarters.
  • Deere & Company's Travere Therapeutics position peaked at $1.39M in Q3 2016.
  • 121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on Deere & Company's 13F filing for Q4 2016, filed 13 Feb 2017.